anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lurasidone Hydrochloride
Trial phase: Phase 3
SMILES: Cl.O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 184
Group description: once daily orally

SM-13496 (lurasidone HCl): SM-13496 20 mg/day for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
Eligibility criteria:
Inclusion Criteria:

Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.
Outpatients aged 18 through 74 years at the time of consent
Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.

Exclusion Criteria:

Patients with imminent risk of suicide or injury to self, others, or property.
Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.
Patients who are otherwise considered ineligible for the study by the investigator.
Intervention: Lurasidone Hydrochloride
Trial phase: Phase 3
SMILES: Cl.O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 169
Group description: once daily orally

SM-13496 (lurasidone HCl): SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Eligibility criteria:
Inclusion Criteria:

Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.
Outpatients aged 18 through 74 years at the time of consent
Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.

Exclusion Criteria:

Patients with imminent risk of suicide or injury to self, others, or property.
Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.
Patients who are otherwise considered ineligible for the study by the investigator.
Intervention: Hydromorphone
Trial phase: Phase 3
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.

Dilaudid: Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
Eligibility criteria:
Inclusion Criteria:

Adult patients who are scheduled for elective Transforaminal Lumbar Interbody Fusion surgery

Exclusion Criteria:

Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.
Inability to follow directions or comprehend the English language.
Females who are pregnant as determined by positive pregnancy test on or before the day of surgery.
Prisoners.
Patient refusal to provide informed consent.
Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine).
Intervention: Bivalirudin
Trial phase: Phase 3
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours

Albuterol-sulphate: Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
Eligibility criteria:
Inclusion Criteria:

1. Diagnosis of familial dysautonomia (Riley-Day syndrome, hereditary sensory and autonomic neuropathy type III) 2. Ages 12 and older: Bronchodilators are routinely used in young children with FD therefore they should be included in this study. The spirometry maneuver is highly dependent on patient cooperation and effort, and FD patients already have limitations that make the spirometry maneuver more problematic to perform such as difficulty with mouth closure and drooling. Therefore, we believe age 12 is a suitable age for FD patients to be included in this study, though in the general population reliable results can be obtained from the age of 6 and sometimes even younger.

3. Patients using Albuterol or Ipratroprium will be included in the study but will be instructed not to take the 24 hours prior to the testing. It is a common practice in clinical medicine to withhold the inhalation drugs prior to performing pulmonary function tests in order to evaluate the response to bronchodilators, an integral part of the test. Patients with an acute respiratory exacerbation will not be enrolled, as withholding bronchodilators would not be advisable.

4. Patients who are taking medications that might affect autonomic function such as anti-hypertensives, beta-blockers, midodrine and florinef will be included in the study and we will record current medication regimen and the time the medication was taken.

Exclusion Criteria:

- 1. Patients who last used inhaled anti-cholinergics or beta-2-agonists within 4-half lives of the drug.

2. Patients with an acute respiratory illness 3. Patients who have had lobectomies. 4. Patients using oxygen therapy throughout the day. 5. Patients who are unable to comply with the study requirements.
Intervention: Bivalirudin
Trial phase: Phase 3
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide

Ipratropium-bromide: Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
Eligibility criteria:
Inclusion Criteria:

1. Diagnosis of familial dysautonomia (Riley-Day syndrome, hereditary sensory and autonomic neuropathy type III) 2. Ages 12 and older: Bronchodilators are routinely used in young children with FD therefore they should be included in this study. The spirometry maneuver is highly dependent on patient cooperation and effort, and FD patients already have limitations that make the spirometry maneuver more problematic to perform such as difficulty with mouth closure and drooling. Therefore, we believe age 12 is a suitable age for FD patients to be included in this study, though in the general population reliable results can be obtained from the age of 6 and sometimes even younger.

3. Patients using Albuterol or Ipratroprium will be included in the study but will be instructed not to take the 24 hours prior to the testing. It is a common practice in clinical medicine to withhold the inhalation drugs prior to performing pulmonary function tests in order to evaluate the response to bronchodilators, an integral part of the test. Patients with an acute respiratory exacerbation will not be enrolled, as withholding bronchodilators would not be advisable.

4. Patients who are taking medications that might affect autonomic function such as anti-hypertensives, beta-blockers, midodrine and florinef will be included in the study and we will record current medication regimen and the time the medication was taken.

Exclusion Criteria:

- 1. Patients who last used inhaled anti-cholinergics or beta-2-agonists within 4-half lives of the drug.

2. Patients with an acute respiratory illness 3. Patients who have had lobectomies. 4. Patients using oxygen therapy throughout the day. 5. Patients who are unable to comply with the study requirements.
Intervention: Biotin
Trial phase: Phase 2
ATC code: A11HA05
SMILES: [H][C@]12CS[C@@H](CCCCC(=O)O)[C@@]1([H])NC(=O)N2
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: 800 IU Vitamin D Supplement

800 IU Vitamin D Supplement: Standard Dose
Eligibility criteria:
Inclusion Criteria:

All participants must be female and at least 21 years of age
Signed informed consent
Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR).
Post-menopausal
Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks
Bisphosphonates are allowed at the treating investigator¡¦s discretion
Performance status (WHO/ECOG scale) 0-2.

Exclusion Criteria:

History of kidney stones
Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters
History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion
Baseline Vitamin D level greater than 50 ng/mL
Inability or unwillingness to comply with, or follow study procedures.
Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat
Malabsorption syndrome, such as Crohn's disease

Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.
Intervention: Allopurinol
Trial phase: Phase 4
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days

allopurinol
Eligibility criteria:
Inclusion Criteria requires both of:

Crystal proven gout, and
An acute gout attack within 72 hours of first treatment

Plus one of the following:

At least 2 gout attacks in past 12 months
Tophus
Nephrolithiasis
24hr urine uric acid greater than 1000mg

Exclusion Criteria:

Inability to return for examinations
Glomerular filtration rate (calculated) less than 50 milliliters per minute
Allopurinol use in past 6 months
Ongoing cancer therapy
Concomitant azathioprine or cyclophosphamide

Any one of the following liver enzymes greater than 1.25 times the upper limit of normal:

AST [Aspartate aminotransferase]
ALT [Alanine aminotransferase]
alkaline phosphatase
Pre-gout pain in involved joint of more than 3 on a scale of 1-10
Neurologic deficit around the involved joint
Intervention: Atorvastatin
Trial phase: Phase 2
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 139
Group description: One 40 mg Atorvastatin tablet each morning by mouth for 24 months

Atorvastatin: 40 mg tablet taken by mouth each morning for 24 months.
Eligibility criteria:
Inclusion Criteria:

Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma Stage I-IV. (Patients should have a > 2 year life expectancy)
Scheduled to receive adjuvant chemotherapy with an Anthracycline (doxorubicin and epirubicin)
21 years of age or older
LVEF > 50% (Most recent within the last 5 years)
Prior administration of anthracyclines is acceptable if therapy was completed > 6 months prior to study enrollment
Patients that are receiving or have received chemotherapy regimens are allowed
Able to hold breath for 10 seconds
Prior cancers allowed if no evidence of disease in last 5 years
Eastern Cooperative Oncology Group (ECOG) 0 or 1

Exclusion Criteria:

Prior use of lipid-lowering therapy within the last 6 months
Current postmenopausal hormone-replacement therapy
Uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg)
Scheduled to receive neoadjuvant chemotherapy with an anthracycline
No active liver disease allowed
Uncontrolled hypothyroidism
Recent history (within past 3 years) of alcohol or drug abuse, inflammatory conditions such as lupus or inflammatory bowel disease, use of immunosuppressant agents, or another medical condition that might compromise safety or the successful completion of the study.
Patients with ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal;pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices.
Unstable angina; significant ventricular arrhythmias (>20 premature ventricular complexes (PVCs)/min due to gating difficulty) atrial fibrillation with uncontrolled ventricular response; coronary artery disease; acute myocardial infarction within 28 days
Current use of Cytochrome P450 (CYP3A4) inhibitors. These include Clarithromycin, HIV protease inhibitors, Itraconazole, grapefruit juice, Cyclosporine, Rifampin or Digoxin
Current or history of hepatic dysfunction
Unable to provide informed consent
Claustrophobia
Planning to move within 24 months of trial enrollment
Pregnant or breast-feeding
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: 1.*1/*1- oral racemic ketamine 0.4 mg/kg

ketamine: 0.4 mg/kg oral racemic ketamine
Eligibility criteria:
Inclusion Criteria:

18-50 yr old
CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion)
Good general health with no remarkable medical conditions
BMI <33
Provided informed consent

Exclusion Criteria:

Known history of liver or kidney disease
Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6
Females who are pregnant or nursing
Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: 2. *1/*6- oral racemic ketamine 0.4 mg/kg

ketamine: 0.4 mg/kg oral racemic ketamine
Eligibility criteria:
Inclusion Criteria:

18-50 yr old
CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion)
Good general health with no remarkable medical conditions
BMI <33
Provided informed consent

Exclusion Criteria:

Known history of liver or kidney disease
Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6
Females who are pregnant or nursing
Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: 3. *6/*6- oral racemic ketamine 0.4 mg/kg

ketamine: 0.4 mg/kg oral racemic ketamine
Eligibility criteria:
Inclusion Criteria:

18-50 yr old
CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion)
Good general health with no remarkable medical conditions
BMI <33
Provided informed consent

Exclusion Criteria:

Known history of liver or kidney disease
Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6
Females who are pregnant or nursing
Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)
Intervention: Losartan
Trial phase: Phase 2
ATC code: C09CA01 | C09DA01 | C09DB06
SMILES: CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.

Losartan: Losartan will be given in increasing doses to those in the losartan arm.
Eligibility criteria:
Inclusion Criteria:

Age 70 and over
Pre-frail as determined by frailty criteria

Exclusion Criteria:

Under age 70
Robust or frail by frailty criteria
Have other indications for use of any angiotensin-receptor blockers (ARB) such as myocardial infarction in past year, history of congestive heart failure, uncontrolled hypertension
Current use of ARBs or angiotensin-converting enzyme (ACE) inhibitors
Prior allergic reaction to or hyperkalemia with losartan or any ARB
Chronic renal failure with a glomerular filtration rate of < 30
Current daily use of non-steroidal anti-inflammatory agents
Current use of steroids
Lower extremity disability that would prevent muscle strength testing
Echocardiogram-diagnosed cardiac failure as evidenced by left ventricular ejection fraction less than 50%
Cognitive impairment with a Mini-Mental State Examination < 24
Intervention: Raltegravir
Trial phase: Phase 4
ATC code: J05AJ01 | J05AR16 | J05AX08
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 54
Group description: Efavirenz 600mg oral at bedtime

Raltegravir: Raltegravir 400mg oral twice daily
Eligibility criteria:
Inclusion Criteria:

Patients who are infected with HIV-1
Patients have not yet received any treatment for HIV
Patients with HIV viral RNA exceeds 5000 copies per ml
Ages at least 20 years

Exclusion Criteria:

Patients with acute or decompensated chronic hepatitis
Patients with chronic hepatitis and serum aminotransferase concentrations are more than five times the upper limit of the normal range
Patients with renal insufficiency (need dialysis or have serum creatinine concentrations of more than twice the upper limit of the normal range
Patients with any medical disorder that the use of study medications is contraindicated
Pregnant or breastfeeding women
Patients who are lack of expectation to maintain assigned study medication during study period
Patients who have received therapy with investigational drugs in the previous 3 months
Intervention: Adcetris
Trial phase: Phase 4
SMILES: CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C)C(O)c1ccccc1)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C(=O)OCc1ccc(NC(=O)C(CCCNC(N)=O)NC(=O)C(NC(=O)CCCCCN2C(=O)CC(S)C2=O)C(C)C)cc1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic toxicity, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
Eligibility criteria:
Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

Male or female participants 18 years or older, with relapsed or refractory classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen

Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:

Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy
Progressive disease during frontline multiagent chemotherapy
Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments
Bidimensional measurable disease
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception at the same time, or agree to practice true abstinence.
Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence.
Clinical laboratory values as specified in the study protocol.

Exclusion Criteria:

Participants who meet any of the following exclusion criteria are not to be enrolled in the study:

Previous treatment with brentuximab vedotin
Previously received an autologous stem cell transplantation (ASCT) or alloSCT
Known cerebral/meningeal disease, including signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML), or any history of PML.
Female participants who are lactating and breastfeeding or pregnant.
Known human immunodeficiency virus (HIV).
Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection.
Grade 2 or higher peripheral neuropathy.
Intervention: Mifepristone
Trial phase: Phase 4
ATC code: G03XB01 | G03XB51
SMILES: [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
Eligibility criteria:
Inclusion Criteria:

>18 years of age
Incidentally noted adrenal nodule <4 cm with benign imaging characteristics
Evidence of mild hypercortisolism
Evidence of diabetes or abnormal glucose tolerance

Exclusion Criteria:

contraindication to mifepristone
Indication for unilateral adrenalectomy
Evidence of other adrenal hormone hypersecretion
lactating mothers
women of childbearing age unwilling to use an effective, nonhormonal form of contraception